Trade Verrica Pharmaceuticals Inc. - VRCA CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
| Spread | 0.05 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026151% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003929% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
Verrica Pharmaceuticals Inc ESG Risk Ratings
‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.
| Prev. Close* | 3.78 |
| Open* | 3.64 |
| 1-Year Change* | 20.93% |
| Day's Range* | 3.64 - 3.87 |
| 52 wk Range | 2.02-8.70 |
| Average Volume (10 days) | 217.68K |
| Average Volume (3 months) | 8.86M |
| Market Cap | 175.83M |
| P/E Ratio | -100.00K |
| Shares Outstanding | 42.06M |
| Revenue | 8.61M |
| EPS | -0.53 |
| Dividend (Yield %) | N/A |
| Beta | 2.02 |
| Next Earnings Date | Nov 6, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Sep 29, 2023 | 3.86 | 0.23 | 6.34% | 3.63 | 3.88 | 3.63 |
| Sep 28, 2023 | 3.78 | 0.10 | 2.72% | 3.68 | 3.83 | 3.64 |
| Sep 27, 2023 | 3.78 | -0.01 | -0.26% | 3.79 | 3.91 | 3.71 |
| Sep 26, 2023 | 3.91 | 0.12 | 3.17% | 3.79 | 4.09 | 3.79 |
| Sep 25, 2023 | 3.89 | 0.20 | 5.42% | 3.69 | 3.90 | 3.67 |
| Sep 22, 2023 | 3.75 | 0.00 | 0.00% | 3.75 | 3.84 | 3.70 |
| Sep 21, 2023 | 3.72 | -0.12 | -3.12% | 3.84 | 3.88 | 3.66 |
| Sep 20, 2023 | 3.97 | 0.13 | 3.39% | 3.84 | 4.12 | 3.84 |
| Sep 19, 2023 | 4.00 | 0.15 | 3.90% | 3.85 | 4.02 | 3.83 |
| Sep 18, 2023 | 3.90 | -0.09 | -2.26% | 3.99 | 4.03 | 3.85 |
| Sep 15, 2023 | 4.01 | -0.06 | -1.47% | 4.07 | 4.13 | 3.96 |
| Sep 14, 2023 | 4.17 | 0.08 | 1.96% | 4.09 | 4.25 | 4.01 |
| Sep 13, 2023 | 4.12 | -0.14 | -3.29% | 4.26 | 4.41 | 4.04 |
| Sep 12, 2023 | 4.27 | 0.13 | 3.14% | 4.14 | 4.30 | 4.01 |
| Sep 11, 2023 | 4.17 | 0.09 | 2.21% | 4.08 | 4.25 | 4.01 |
| Sep 8, 2023 | 4.25 | 0.08 | 1.92% | 4.17 | 4.33 | 4.06 |
| Sep 7, 2023 | 4.16 | -0.06 | -1.42% | 4.22 | 4.22 | 4.08 |
| Sep 6, 2023 | 4.20 | -0.13 | -3.00% | 4.33 | 4.42 | 4.18 |
| Sep 5, 2023 | 4.33 | -0.11 | -2.48% | 4.44 | 4.56 | 4.32 |
| Sep 1, 2023 | 4.60 | 0.14 | 3.14% | 4.46 | 4.76 | 4.34 |
Verrica Pharmaceuticals Inc. Events
| Time (UTC) | Country | Event |
|---|---|---|
| Monday, November 6, 2023 | ||
| Time (UTC) 10:59 | Country US
| Event Q3 2023 Verrica Pharmaceuticals Inc Earnings Release Q3 2023 Verrica Pharmaceuticals Inc Earnings ReleaseForecast -Previous - |
| Monday, February 19, 2024 | ||
| Time (UTC) 13:30 | Country US
| Event Q4 2023 Verrica Pharmaceuticals Inc Earnings Release Q4 2023 Verrica Pharmaceuticals Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total revenue | 9.032 | 12 | 0 | 0 | 0 |
| Revenue | 9.032 | 12 | 0 | 0 | |
| Total Operating Expense | 31.765 | 42.908 | 40.181 | 30.08 | 21.878 |
| Selling/General/Admin. Expenses, Total | 17.405 | 26.979 | 24.508 | 14.644 | 9.052 |
| Research & Development | 12.198 | 15.929 | 15.673 | 15.436 | 12.826 |
| Operating Income | -22.733 | -30.908 | -40.181 | -30.08 | -21.878 |
| Interest Income (Expense), Net Non-Operating | -1.696 | -4.172 | -2.512 | 1.877 | 1.231 |
| Net Income Before Taxes | -24.487 | -35.08 | -42.694 | -28.207 | -20.648 |
| Net Income After Taxes | -24.487 | -35.08 | -42.694 | -28.207 | -20.648 |
| Net Income Before Extra. Items | -24.487 | -35.08 | -42.694 | -28.207 | -20.648 |
| Net Income | -24.487 | -35.08 | -42.694 | -28.207 | -20.648 |
| Income Available to Common Excl. Extra. Items | -24.487 | -35.08 | -42.694 | -28.207 | -20.648 |
| Income Available to Common Incl. Extra. Items | -24.487 | -35.08 | -42.694 | -28.207 | -20.648 |
| Diluted Net Income | -24.487 | -35.08 | -42.694 | -28.207 | -20.648 |
| Diluted Weighted Average Shares | 34.1634 | 27.0445 | 24.9956 | 24.8979 | 25.8099 |
| Diluted EPS Excluding Extraordinary Items | -0.71676 | -1.29712 | -1.70806 | -1.13291 | -0.8 |
| Dividends per Share - Common Stock Primary Issue | |||||
| Diluted Normalized EPS | -0.6747 | -1.29712 | -1.70806 | -1.13291 | -0.8 |
| Other, Net | -0.058 | -0.001 | -0.004 | -0.001 | |
| Total Adjustments to Net Income | 0 | ||||
| Cost of Revenue, Total | 0.725 | ||||
| Gross Profit | 8.307 | ||||
| Unusual Expense (Income) | 1.437 |
| Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
|---|---|---|---|---|---|
| Total revenue | 0.182 | 0.037 | 0.068 | 8.319 | 0.214 |
| Revenue | 0.182 | 0.037 | 0.068 | 8.319 | 0.214 |
| Total Operating Expense | 11.798 | 7.126 | 6.279 | 8.308 | 9.335 |
| Selling/General/Admin. Expenses, Total | 5.937 | 4.319 | 3.189 | 3.925 | 5.173 |
| Research & Development | 5.725 | 2.739 | 2.365 | 2.946 | 4.162 |
| Operating Income | -11.616 | -7.089 | -6.211 | 0.011 | -9.121 |
| Interest Income (Expense), Net Non-Operating | 0.626 | 0.5 | 0.286 | 0.067 | -1.046 |
| Net Income Before Taxes | -10.99 | -6.589 | -5.932 | 0.083 | -10.168 |
| Net Income After Taxes | -10.99 | -6.589 | -5.932 | 0.083 | -10.168 |
| Net Income Before Extra. Items | -10.99 | -6.589 | -5.932 | 0.083 | -10.168 |
| Net Income | -10.99 | -6.589 | -5.932 | 0.083 | -10.168 |
| Income Available to Common Excl. Extra. Items | -10.99 | -6.589 | -5.932 | 0.083 | -10.168 |
| Income Available to Common Incl. Extra. Items | -10.99 | -6.589 | -5.932 | 0.083 | -10.168 |
| Diluted Net Income | -10.99 | -6.589 | -5.932 | 0.083 | -10.168 |
| Diluted Weighted Average Shares | 45.9169 | 43.0234 | 41.1702 | 44.6562 | 27.5191 |
| Diluted EPS Excluding Extraordinary Items | -0.23935 | -0.15315 | -0.14408 | 0.00186 | -0.36949 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | -0.23935 | -0.15315 | -0.14408 | 0.03404 | -0.36949 |
| Other, Net | 0 | -0.007 | 0.005 | -0.001 | |
| Unusual Expense (Income) | 0 | 1.437 | |||
| Cost of Revenue, Total | 0.136 | 0.068 | 0.725 | ||
| Gross Profit | 0.046 | -0.031 | -0.657 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total Current Assets | 39.115 | 74.328 | 67.65 | 64.983 | 91.152 |
| Cash and Short Term Investments | 34.273 | 70.354 | 65.47 | 62.017 | 89.809 |
| Cash & Equivalents | 34.273 | 15.752 | 10.686 | 9.241 | 10.271 |
| Prepaid Expenses | 4.355 | 3.974 | 2.18 | 2.966 | 1.343 |
| Total Assets | 44.721 | 80.125 | 74.154 | 68.424 | 91.906 |
| Total Current Liabilities | 3.459 | 46.055 | 39.475 | 3.351 | 2.477 |
| Accounts Payable | 0.507 | 0.845 | 0.348 | 1.185 | 0.922 |
| Payable/Accrued | 0.038 | ||||
| Accrued Expenses | 2.952 | 3.511 | 3.312 | 2.166 | 1.517 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 4.688 | 47.52 | 41.168 | 3.409 | 2.477 |
| Total Long Term Debt | 0 | 0.016 | 0 | 0 | 0 |
| Total Equity | 40.033 | 32.605 | 32.986 | 65.015 | 89.429 |
| Redeemable Preferred Stock | 0 | ||||
| Common Stock | 0.004 | 0.003 | 0.003 | 0.003 | 0.003 |
| Additional Paid-In Capital | 203.482 | 171.597 | 136.868 | 126.594 | 122.526 |
| Retained Earnings (Accumulated Deficit) | -163.453 | -138.966 | -103.886 | -61.192 | -33.083 |
| Total Liabilities & Shareholders’ Equity | 44.721 | 80.125 | 74.154 | 68.424 | 91.906 |
| Total Common Shares Outstanding | 41.0941 | 27.5191 | 25.4411 | 25.807 | 25.7048 |
| Property/Plant/Equipment, Total - Net | 5.33 | 5.502 | 4.938 | 2.201 | 0.255 |
| Other Long Term Assets, Total | 0.276 | 0.295 | 1.566 | 1.24 | 0.499 |
| Treasury Stock - Common | 0 | 0 | 0 | 0 | |
| Short Term Investments | 0 | 54.602 | 54.784 | 52.776 | 79.538 |
| Property/Plant/Equipment, Total - Gross | 6.029 | 5.756 | 5.065 | 2.285 | 0.275 |
| Accumulated Depreciation, Total | -0.699 | -0.254 | -0.127 | -0.084 | -0.02 |
| Other Equity, Total | -0.029 | 0.001 | -0.39 | -0.017 | |
| Other Liabilities, Total | 1.229 | 1.449 | 1.693 | 0.058 | |
| Current Port. of LT Debt/Capital Leases | 0 | 41.699 | 35.315 | ||
| Other Current Liabilities, Total | 0 | 0.5 | |||
| Capital Lease Obligations | 0 | 0.016 | |||
| Total Receivables, Net | 0.487 | ||||
| Long Term Debt | 0 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Total Current Assets | 63.097 | 39.115 | 43.395 | 57.341 | 65.772 |
| Cash and Short Term Investments | 59.952 | 34.273 | 39.454 | 14.398 | 21.904 |
| Cash & Equivalents | 59.952 | 34.273 | 32.473 | 5.43 | 10.407 |
| Short Term Investments | 0 | 6.981 | 8.968 | 11.497 | |
| Total Receivables, Net | 0.056 | 0.487 | 0.419 | 0.218 | 0.431 |
| Prepaid Expenses | 3.089 | 4.355 | 3.522 | 2.725 | 3.437 |
| Total Assets | 68.639 | 44.721 | 49.147 | 63.436 | 71.617 |
| Property/Plant/Equipment, Total - Net | 5.173 | 5.33 | 5.531 | 5.626 | 5.703 |
| Property/Plant/Equipment, Total - Gross | 6.003 | 6.029 | 6.1 | 6.076 | 6.055 |
| Accumulated Depreciation, Total | -0.83 | -0.699 | -0.569 | -0.45 | -0.352 |
| Other Long Term Assets, Total | 0.369 | 0.276 | 0.221 | 0.469 | 0.142 |
| Total Current Liabilities | 2.643 | 3.459 | 3.078 | 45.711 | 44.8 |
| Accounts Payable | 0.575 | 0.507 | 0.137 | 0.714 | 0.531 |
| Accrued Expenses | 2.068 | 2.952 | 2.941 | 2.697 | 2.264 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 0 | 0 | 42.3 | 42.005 | |
| Other Current Liabilities, Total | |||||
| Total Liabilities | 3.793 | 4.688 | 4.382 | 47.103 | 46.199 |
| Total Long Term Debt | 0 | 0 | 0 | 0.013 | 0.015 |
| Other Liabilities, Total | 1.15 | 1.229 | 1.304 | 1.379 | 1.384 |
| Total Equity | 64.846 | 40.033 | 44.765 | 16.333 | 25.418 |
| Common Stock | 0.004 | 0.004 | 0.004 | 0.003 | 0.003 |
| Additional Paid-In Capital | 234.884 | 203.482 | 202.311 | 173.998 | 172.913 |
| Retained Earnings (Accumulated Deficit) | -170.042 | -163.453 | -157.521 | -157.604 | -147.436 |
| Treasury Stock - Common | 0 | 0 | 0 | 0 | |
| Other Equity, Total | -0.029 | -0.064 | -0.062 | ||
| Total Liabilities & Shareholders’ Equity | 68.639 | 44.721 | 49.147 | 63.436 | 71.617 |
| Total Common Shares Outstanding | 41.8521 | 41.0941 | 41.0941 | 27.5191 | 27.5191 |
| Capital Lease Obligations | 0 | 0 | 0.013 | 0.015 | |
| Other Current Assets, Total | 40 | 40 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -24.487 | -35.08 | -42.694 | -28.207 | -20.648 |
| Cash From Operating Activities | -18.65 | -27.582 | -30.207 | -27.408 | -17.874 |
| Non-Cash Items | 7.183 | 7.789 | 10.809 | 2.463 | 1.816 |
| Cash Interest Paid | 1.789 | 2.85 | 1.875 | 0 | 0 |
| Changes in Working Capital | -1.8 | -0.535 | 1.635 | -1.728 | 0.938 |
| Cash From Financing Activities | -16.87 | 33.646 | 35.232 | 0.423 | 99.376 |
| Financing Cash Flow Items | -0.017 | 0 | 0.319 | 0 | -7.881 |
| Issuance (Retirement) of Stock, Net | 26.901 | 28.676 | 0.453 | 0.423 | 107.257 |
| Net Change in Cash | 18.521 | 5.066 | 1.445 | -1.03 | 1.608 |
| Cash From Operating Activities | 0.454 | 0.244 | 0.043 | 0.064 | 0.02 |
| Cash From Investing Activities | 54.041 | -0.998 | -3.58 | 25.955 | -79.894 |
| Capital Expenditures | -0.302 | -0.883 | -1.47 | -0.682 | -0.275 |
| Other Investing Cash Flow Items, Total | 54.343 | -0.115 | -2.11 | 26.637 | -79.619 |
| Issuance (Retirement) of Debt, Net | -43.754 | 4.97 | 34.46 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -6.589 | -24.487 | -18.555 | -18.638 | -8.47 |
| Cash From Operating Activities | -4.59 | -18.65 | -13.696 | -15.521 | -8.34 |
| Cash From Operating Activities | 0.131 | 0.454 | 0.323 | 0.196 | 0.098 |
| Non-Cash Items | 1.165 | 7.183 | 5.92 | 3.228 | 1.725 |
| Cash Interest Paid | 0 | 1.789 | 1.788 | 1.468 | 0.725 |
| Changes in Working Capital | 0.703 | -1.8 | -1.384 | -0.307 | -1.693 |
| Cash From Investing Activities | -0.011 | 54.041 | 47.287 | 45.218 | 43.013 |
| Capital Expenditures | -0.011 | -0.302 | -0.236 | -0.159 | -0.005 |
| Other Investing Cash Flow Items, Total | 0 | 54.343 | 47.523 | 45.377 | 43.018 |
| Cash From Financing Activities | 30.28 | -16.87 | -16.87 | -0.019 | -0.018 |
| Issuance (Retirement) of Stock, Net | 30.308 | 26.901 | 26.901 | 0 | 0 |
| Issuance (Retirement) of Debt, Net | 0 | -43.754 | -43.754 | -0.002 | -0.001 |
| Net Change in Cash | 25.679 | 18.521 | 16.721 | 29.678 | 34.655 |
| Financing Cash Flow Items | -0.028 | -0.017 | -0.017 | -0.017 | -0.017 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Verrica Pharmaceuticals Inc. Company profile
About Verrica Pharmaceuticals Inc
Verrica Pharmaceuticals Inc. is a dermatology therapeutics company. The Company is focused on developing and commercializing novel treatments for skin diseases. Its lead product candidate, VP-102, is a drug-device combination of topical solution of cantharidin, a widely recognized, naturally sourced agent to treat topical dermatological conditions, administered through single-use precision applicator. The Company is developing VP-102 for the treatment of molluscum contagiosum, or molluscum, a contagious and primarily pediatric viral skin disease, and common warts. It is conducting Phase II clinical trial for the treatment of plantar warts.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Verrica Pharmaceuticals Inc revenues increased from $0K to $12M. Net loss decreased 18% to $35.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Stock-Based Compensation in SG&A decrease of 50% to $4.5M (expense), Research and development - Balancing val decrease of 3% to $14.4M (expense).
| Industry: | Pharmaceuticals (NEC) |
10 N High St Ste 200
WEST CHESTER
PENNSYLVANIA 19380-3014
US
Income Statement
- Annual
- Quarterly
News
How to Trade The Triple Top
Welcome to Part 5 of our 7-part Power Patterns series. In this series, we'll be equipping you with the skills to trade some of the most indicative price patterns which occur on any timeframe in every market.
14:13, 27 September 2023
Q4 lookahead: US indices starting to show signs of trouble?
US indices start to draw attention as traders focus on the outlook for Q4.
07:20, 27 September 2023
USD/JPY Climbs Towards Key Highs
USDJPY’s powerful long-term uptrend has been reignited after last week’s sharply contrasting policy statements from the Federal Reserve and Bank of Japan.
11:32, 26 September 2023
EUR/USD tests key support
EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.
14:32, 21 September 2023
BoE leaves rates unchanged, GBP drops further as investors look for more clarity
The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August
11:45, 21 September 2023
GBP softer after CPI surprise, JPY focused on any further hints from Ueda
GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.
12:42, 20 September 2023
How to Trade The Break & Retest
In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.
11:59, 20 September 2023People also watch
Still looking for a broker you can trust?
Join the 555.000+ traders worldwide that chose to trade with Capital.com